Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

被引：7

作者：

Dougados, Maxime ^{[1
,2
]}

Charles-Schoeman, Christina ^{[3
]}

Szekanecz, Zoltan ^{[4
]}

Giles, Jon T. ^{[5
]}

Ytterberg, Steven R. ^{[6
]}

Bhatt, Deepak L. ^{[7
]}

Koch, Gary G. ^{[8
]}

Vranic, Ivana ^{[9
]}

Wu, Joseph ^{[10
]}

Wang, Cunshan ^{[10
]}

Kwok, Kenneth ^{[11
]}

Menon, Sujatha ^{[10
]}

Connell, Carol A. ^{[10
]}

Yndestad, Arne ^{[12
]}

Rivas, Jose L. ^{[13
]}

Buch, Maya H. ^{[14
,15
]}

机构：

[1] Univ Paris, Hop Cochin, Assistance Publ Hop Paris, Dept Rheumatol, Paris, France

[2] PRES Sorbonne Paris Cite, INSERM, U1153 Clin Epidemiol & Biostat, Paris, France

[3] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90024 USA

[4] Univ Debrecen, Fac Med, Div Rheumatol, Debrecen, Hungary

[5] Columbia Univ, Vagelos Coll Phys & Surg, Div Rheumatol, New York, NY USA

[6] Mayo Clin, Div Rheumatol, Rochester, MN USA

[7] Icahn Sch Med Mt Sinai Hlth Syst, Mt Sinai Heart, New York, NY USA

[8] Univ North Carolina Chapel Hill, Dept Biostat, Chapel Hill, NC USA

[9] Pfizer Ltd, Tadworth, England

[10] Pfizer Inc, Groton, CT USA

[11] Pfizer Inc, New York, NY USA

[12] Pfizer Inc, Oslo, Norway

[13] Pfizer SLU, Madrid, Spain

[14] Univ Manchester, Ctr Musculoskeletal Res, Div Musculoskeletal & Dermatol Sci, Fac Biol Med & Hlth, Manchester, Lancs, England

[15] Manchester Univ Hosp NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷 / 04期

关键词：

Arthritis; Rheumatoid; Cardiovascular Diseases; Antirheumatic Agents;

D O I：

10.1136/ard-2022-223406

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The ORAL Surveillance trial found that patients with rheumatoid arthritis (RA) aged ≥50 years with ≥1 additional cardiovascular (CV) risk factor had an increased risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi).1 A post hoc analysis indicated that the increased risk of MACE with tofacitinib versus TNFi was apparent primarily in patients with a history of atherosclerotic CV disease (ASCVD), that is, pre-existing coronary artery, cerebrovascular or peripheral artery disease.2 © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

引用

页码：575 / 577

页数：3

共 50 条

[1] IMPACT OF BASELINE CARDIOVASCULAR RISK ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
Dougados, M.
Charles-Schoeman, C.
Szekanecz, Z.
Giles, J. T.
Ytterberg, S. R.
Bhatt, D. L.
Koch, G. G.
Vranic, I.
Wu, J.
Wang, C.
Kwok, K.
Menon, S.
Connell, C. A.
Yndestad, A.
Rivas, J. L.
Buch, M. H.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 175 - 176
[2] CARDIOVASCULAR AND ADVERSE EVENTS RISK WITH TOFACITINIB IN RHEUMATOID ARTHRITIS IN THE DOMINICAN REPUBLIC
Alvarez Santana, R. A.
Garcia, D.
Perez, L.
Polanco Mora, T.
Concepcion Sanchez, L.
Paulino, I.
Mercedes, I.
Rodriguez Bautista, E.
Valdez, T.
Feriz, A.
Munoz Louis, R.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1446 - 1447
[3] Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis
Mal, Kheraj
Kumar, Ratan
Mansoor, Farah
Kaur, Navneet
Kumar, Anil
Memon, Sidra
Rizwan, Amber
[J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)
[4] Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme
Schreiber, Stefan
Rubin, David T.
Ng, Siew C.
Peyrin-Biroulet, Laurent
Danese, Silvio
Modesto, Irene
Guo, Xiang
Su, Chinyu
Kwok, Kenneth K.
Jo, Hyejin
Chen, Yan
Yndestad, Arne
Reinisch, Walter
Dubinsky, Marla C.
[J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 (11): : 1761 - 1770
[5] INFLUENZA ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE TOFACITINIB CLINICAL PROGRAMME
Winthrop, K.
Yndestad, A.
Henrohn, D.
Jo, H.
Marsal, S.
Galindo-Izquierdo, M.
Diehl, A.
Shapiro, A.
Cohen, S. B.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1149 - 1150
[6] Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis
Karpouzas, George Athanasios
Ormseth, Sarah R.
van Riel, Piet Leonardus Cornelis Maria
Gonzalez-Gay, Miguel A.
Corrales, Alfonso
Rantapaa-Dahlqvist, Solbritt
Sfikakis, Petros P.
Dessein, Patrick
Tsang, Linda
Hitchon, Carol
El-Gabalawy, Hani
Pascual-Ramos, Virginia
Contreras-Yanez, Irazu
Colunga-Pedraza, Iris J.
Galarza-Delgado, Dionicio Angel
Azpiri-Lopez, Jose Ramon
Semb, Anne Grete
Misra, Durga Prasanna
Hauge, Ellen-Margrethe
Kitas, George
[J]. RMD OPEN, 2024, 10 (03):
[7] Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis
Lauper, Kim
Courvoisier, Delphine S.
Chevallier, Paola
Finckh, Axel
Gabay, Cem
[J]. ARTHRITIS CARE & RESEARCH, 2018, 70 (12) : 1756 - 1763
[8] ASSOCIATION BETWEEN BASELINE CARDIOVASCULAR RISK AND INCIDENCE RATES OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MALIGNANCIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS RECEIVING TOFACITINIB
Kristensen, L. E.
Strober, B.
Poddubnyy, D.
Leung, Y. Y.
Jo, H.
Kwok, K.
Vranic, I.
Fleishaker, D.
Fallon, L.
Yndestad, A.
Gladman, D. D.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 20 - 20
[9] Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
Kristensen, Lars E.
Strober, Bruce
Poddubnyy, Denis
Leung, Ying-Ying
Jo, Hyejin
Kwok, Kenneth
Vranic, Ivana
Fleishaker, Dona L.
Fallon, Lara
Yndestad, Arne
Gladman, Dafna D.
[J]. THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2023, 15
[10] Risk Factors for Major Adverse Cardiovascular Events in Rheumatoid Arthritis Patients Treated with Tocilizumab
Rao, Vijay
Pavlov, Andrey
Klearman, Micki
Musselman, David
Giles, Jon T.
Bathon, Joan M.
Sattar, Naveed
Lee, Janet S.
[J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S642 - S642

← 1 2 3 4 5 →